Neuromuscular play NMD raises EUR38M in series A

NMD Pharma ApS (Aarhus, Denmark) raised €38 million ($46.6 million) in a tranched series A round led by new investor INKEF on March 22. Fellow new investor Roche Venture Fund and existing investors Novo Seeds and Lundbeckfonden Emerge also participated.

The company is developing inhibitors against chloride voltage-gated channel 1 (CLCN1; CLC1), which is specific to skeletal muscle fibers and inhibits nerve-to-muscle communication at the neuromuscular junction (see BioCentury, June 23, 2016)...